Products An inhalable insulin preparation containing a rapid-acting human insulin was approved in the United States in 2014 (Afrezza, powder inhalation). The drug has not yet been registered in many countries. Pfizer’s first inhalable insulin Exubera was withdrawn from the market in 2007 for commercial reasons; see Exubera. Structure and properties Human insulin (C257H383N65O77S6, Mr … Inhalable Insulin
Explanation/Definition Actraphane® is a mixed insulin preparation. This means that it contains both short- and long-acting insulins. The short-acting normal insulin develops its blood-sugar-lowering effect after only half an hour, while the effect of the slow-acting delay insulin is maintained for up to 24 hours. Trade names Actraphane® 30/-50, Penfill 100 I. U. /ml, injection … Actraphane®
Dosage The dosage of Actraphane is different for each patient and should always be discussed with the doctor. The required dose depends on the age, weight, physical activity and eating habits of the patient. In general, an average of 0.3 to 1.0 International Units of Insulin per kilogram of body weight of the patient are … Dosage | Actraphane®
